CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Total net revenue	$ 151,954,000	$ 128,782,000	$ 436,091,000	$ 371,023,000
COST OF REVENUE	89,643,000	79,889,000	259,075,000	239,952,000
GROSS PROFIT	62,311,000	48,893,000	177,016,000	131,071,000
Operating expenses:
General and administrative	61,486,000	64,282,000	183,343,000	188,481,000
Research and development	5,285,000	7,312,000	20,182,000	23,651,000
Sales and marketing	17,610,000	16,809,000	52,770,000	50,179,000
Restructuring charges	2,125,000	0	9,883,000	0
Total operating expenses	86,506,000	88,403,000	266,178,000	262,311,000
LOSS FROM OPERATIONS	(24,195,000)	(39,510,000)	(89,162,000)	(131,240,000)
Interest (income) expense, net	(2,840,000)	139,000	(6,831,000)	2,366,000
Other expense (income), net	96,000	(25,000)	(520,000)	212,000
Loss before taxes	(21,451,000)	(39,624,000)	(81,811,000)	(133,818,000)
Income tax benefit	(2,935,000)	(2,772,000)	(8,169,000)	(12,255,000)
NET LOSS	$ (18,516,000)	$ (36,852,000)	$ (73,642,000)	$ (121,563,000)
NET LOSS PER SHARE
Basic (in dollars per share)	$ (0.15)	$ (0.30)	$ (0.59)	$ (0.98)
Diluted (in dollars per share)	$ (0.15)	$ (0.30)	$ (0.59)	$ (0.98)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic (in shares)	125,687	124,425	125,358	124,055
Diluted (in shares)	125,687	124,425	125,358	124,055
Clinical Services
Total net revenue	$ 127,553,000	$ 106,162,000	$ 365,578,000	$ 310,588,000
COST OF REVENUE	73,994,000	65,261,000	213,032,000	197,563,000
GROSS PROFIT	53,559,000	40,901,000	152,546,000	113,025,000
Advanced Diagnostics
Total net revenue	24,401,000	22,620,000	70,513,000	60,435,000
COST OF REVENUE	15,649,000	14,628,000	46,043,000	42,389,000
GROSS PROFIT	$ 8,752,000	$ 7,992,000	$ 24,470,000	$ 18,046,000